Navigation Links
Progenika Biopharma Grants Grifols World-Wide Distribution Rights for the BLOODCHIP® Genotyping Test for Blood Donors
Date:6/24/2010

BARCELONA, Spain, June 24 /PRNewswire/ -- Spanish biotechnology company Progenika Biopharma, specializing in the development of personal medicine technology, has granted Grifols exclusive world-wide distribution rights for its BLOODCHIP® molecular biology products.  BLOODCHIP® products are used for genotyping of blood donors to assure the compatibility of blood for transfusion between donor and recipient.

Under this agreement, Grifols takes a further step towards the consolidation of its Diagnostic division, expanding its range of products at the leading edge of immunohematology technology.   In addition, Grifols' presence in more than 90 countries will global distribution of the BLOODCHIP® product line.  Likewise, the international presence of Grifols in more than 90 countries through the 22 Grifols' affiliates assures effective global distribution of the test.  

The new product line is expected to generate revenues of between euro 50 and euro 100 million over the next 5 years. Although the use of molecular biology tests in transfusion compatibility is still at its early stages, its use is expected to become more widespread as a result of the hemovigilance and transfusion safety plans being introduced in many countries.

Victor Grifols, President and CEO of Grifols stated: "This agreement will allow us to strengthen our Diagnostic Division and consolidate our global position in the field of blood grouping with a new innovative tool that increases transfusion safety."  For his part, Antonio Martinez, CEO of Progenika, noted that, "This distribution agreement ensures that our products will be properly marketed, and allows us to focus on the development of new diagnostic and therapeutic tools that improve quality of life."

About the BLOODCHIP® test

BLOODCHIP® is an integrated circuit that determines the main allelic variants of blood groups and platelet antigens by analyzing 128 genetic polymorphisms.  The test is used to prevent potential transfusion reactions in those patients for whom conventional serological tests are insufficient.

The BLOODCHIP® test already holds a CE mark for marketing in Europe and has been developed by the Bloodgen Consortium, a leading European group consisting of blood banks, research institutes and Progenika Biopharma, SA., whose mission is to improve patient safety and transfusion compatibility by blood group and genotype.  

About Grifols

Grifols is a Spanish holding company, specializing in the hospital-pharmaceutical sector, and with a presence in over 90 countries. Since May 2006 it has been listed on the Spanish Continuous Market, and since 2008 it has been included in the Ibex-35. It focuses on the research, development, manufacture and marketing of plasma products, diagnostic systems, intravenous therapies, enteral nutrition and medical supplies. In recent years Grifols has made significant investments in the area of transfusionmedicine to ensure the strategic and technological position of the company in this area.

About Progenika

Progenika, a Spanish company which specializes in personalized medicine., develops DNA biochips for the diagnosis, prognosis and prediction of response to treatment of complex human illnesses. Progenika offers DNA based tests in areas such as: oncology, the lipids, Nervous System diseases or the optimization of its treatments. Among its out-standing products, in addition to the BLOODchip, they find the LIPOchip, PHARMAchip, Promonitor, BRAINchip.  Progenika was founded in 2000. Its development and production centers are located in the Zamudio Technology Park (in Spain) and in Cambridge (Massachusetts, USA), and it has commercial and intellectual property management offices in Madrid and London. Over 140 scientists are currently employed by the company, which products are commercialized in America, Europe and Middle East.

For more information please visit www.grifols.com.


'/>"/>
SOURCE Grifols, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Therapure Biopharma Inc. Signs Biomanufacturing Contract with ProChon Biotech Ltd.
2. Chinese Biopharmaceutical Association Holds 15th Annual Conference in Rockville, MD, June 12 - 13
3. IntraLinks Announces Partnership With SAFE-BioPharma; Will Provide Digital Identity Capabilities With its Life Sciences Solutions
4. PDL BioPharma to Announce First Quarter 2010 Financial Results and Hold Conference Call on April 29, 2010
5. PDL BioPharma Announces Fourth Quarter and Full Year 2009 Financial Results and Provides First Quarter 2010 Revenue Guidance
6. ClearTrial Launches New Service to Bring Speed and Accuracy in Clinical Trial Planning Within Reach of Smaller Biopharma Companies
7. Indiana Biopharmaceutical Service Providers Maintain Steady Growth Despite Industry Challenges
8. SynCo Bio Partners Signs New Manufacturing Agreements to Supply the US Market; Securing its Position as a Market Leader in Microbial Biopharmaceutical Contract Production
9. ClearTrial to Demonstrate Dramatic Gains in Clinical Outsourcing Efficiency Achieved by Biopharmaceutical Companies at European Outsourcing Event
10. Sinobiopharma Announces Second Quarter 2010 Financial Results
11. Microbix And Therapure Biopharma Form Partnership To Expand Water-Based Supplies To The Pharma Industry
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... San Diego, CA (PRWEB) , ... June 27, 2016 , ... ... mClinical solutions for clinical trials, announced today the Clinical Reach Virtual Patient ... and their care circle with the physician and clinical trial team. , Using the ...
(Date:6/27/2016)... PHILADELPHIA , June 27, 2016  Liquid ... today announced the funding of a Sponsored Research ... study circulating tumor cells (CTCs) from cancer patients.  ... changes in CTC levels correlate with clinical outcomes ... therapies. These data will then be employed to ...
(Date:6/24/2016)... DIEGO , June 24, 2016 ... more sensitively detects cancers susceptible to PARP inhibitors ... circulating tumor cells (CTCs). The new test has ... HRD-targeted therapeutics in multiple cancer types. ... targeting DNA damage response pathways, including PARP, ATM, ...
(Date:6/23/2016)... , ... June 23, 2016 , ... ... release of its second eBook, “Clinical Trials Patient Recruitment and Retention Tips.” Partnering ... retention in this eBook by providing practical tips, tools, and strategies for clinical ...
Breaking Biology Technology:
(Date:6/9/2016)... June 9, 2016 Paris ... Teleste,s video security solution to ensure the safety of people ... during the major tournament Teleste, an international ... and services, announced today that its video security solution will ... to back up public safety across the country. The system ...
(Date:6/2/2016)... , June 2, 2016   The Weather Company ... announcing Watson Ads, an industry-first capability in which consumers will ... being able to ask questions via voice or text and ... Marketers have long sought an ... consumer, that can be personal, relevant and valuable; and can ...
(Date:5/20/2016)... MINNEAPOLIS , May 20, 2016  VoiceIt ... technology partnership with VoicePass. By working ... user experience.  Because VoiceIt and VoicePass take slightly ... two engines increases both security and usability. ... expressed excitement about this new partnership. ...
Breaking Biology News(10 mins):